Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan

Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan–cetuximab

Published:2012-07 Issue:7 Volume:23 Page:1706-1712
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Scartozzi M.,Giampieri R.,Maccaroni E.,Mandolesi A.,Giustini L.,Silva R.,Zaniboni A.,Biscotti T.,Biagetti S.,Galizia E.,Loupakis F.,Falcone A.,Bearzi I.,Cascinu S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/7/1706/16703371/mdr558.pdf

Reference38 articles.

1. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer;Van Cutsem;N Engl J Med,2009

2. KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab;Lievre;J Clin Oncol,2008

3. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy;Di Fiore;Br J Cancer,2007

4. Oncogenic activation of RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies;Benvenuti;Cancer Res,2007

5. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer;Di Nicolantonio;J Clin Oncol,2008

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis;BMC Cancer;2023-11-16

2. The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer: A Turkish Oncology Group (TOG) study;Journal of Cancer Research and Clinical Oncology;2023-02-20

3. A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab;Journal of Gastrointestinal Oncology;2022-12

4. Drug Resistance in Colorectal Cancer: From Mechanism to Clinic;Cancers;2022-06-14

5. Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab;Frontiers in Oncology;2021-09-30